There’s still money to be raised by gene therapy startups with good clinical data. On Wednesday, North Carolina biotech Atsena Therapeutics said it had raised a $150 million Series C to try and be the first to treat a rare form of ocular disease that leads to blindness. Bain Capital Life Sciences led the financing. […]

Funding to Advance New Histotripsy Applications and Launch Innovative BOOMBOX Master Study HistoSonics Edison® Histotripsy System (Photo: Business Wire) August 15, 2024 08:00 AM Eastern Daylight Time MINNEAPOLIS–(BUSINESS WIRE)–HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced today the completion of an oversubscribed $102 million Series D financing. The round was […]

For Marco B. Zoccali, MD, FACS, a colorectal surgeon at NewYork-Presbyterian/Columbia, sacral nerve stimulation (SNS) has been a routine part of the care he provides to his patients with fecal incontinence. Now, as part of a clinical trial, Dr. Zoccali is investigating the use of SNS in his patients with inflammatory bowel disease (IBD).    The […]

Company also secures $9.5 million in Series A funding to expand its resources to meet rapidly growing customer demand   PALO ALTO, Calif.–(BUSINESS WIRE)–Huma.AI has expanded its self-service business intelligence platform to include a post-market surveillance (PMS) solution specifically designed to help device and IVD manufacturers meet stringent new compliance and oversight requirements required by the […]

Proceeds Used to Acquire ClinEdge and Invest Further in Technology & Data Platform SAN FRANCISCO–(BUSINESS WIRE)– Morgan Stanley Expansion Capital and Ally Bridge Group, today announced the firms have completed an investment in Elligo Health Research®, (“Elligo”), a healthcare-enabling research organization powered by the novel IntElligo® technology. The $135 million Series E financing also included participation […]

FREDERICK, Md., June 16, 2021 /PRNewswire/ — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the closing of a $16.6 million Series A financing.  The round was led by Hatteras Venture Partners with participation from Genesys Capital, Point Field Partners and Alexandria Venture Investments […]

– COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy – – Myeloprotective efficacy of COSELA resulted in reductions in the incidence and duration of severe neutropenia, and impacted anemia and the need for rescue interventions such as growth factors and red […]

Phase 1/2 “INTREPID” trial to evaluate safety and ability of engineered FGF-1 to regenerate corneal endothelial cells August 19, 2020 07:00 AM Eastern Daylight Time SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the regenerative treatment of people with corneal endothelial dystrophies […]

PhaseBio receives clearance of IND application from U.S. FDA under Coronavirus Treatment Acceleration Program (CTAP) “VANGARD” trial will assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome Based on FDA feedback, PhaseBio believes that positive, clearly interpretable and clinically meaningful trial results may […]

NASHVILLE, Tenn.–(BUSINESS WIRE)–HealthStream (Nasdaq: HSTM), a leading provider of workforce and provider solutions for the healthcare industry, today announced that it has acquired NurseGrid, a Portland, Oregon-based healthcare technology company. Through this acquisition, the Company gains NurseGrid Mobile, the #1 rated and top downloaded app for nurses, and its corollary application for nurse managers, NurseGrid […]

PhaseBio to receive up to $120 million in development funding PhaseBio retains exclusive worldwide commercial rights to PB2452 MALVERN, Pa. and SAN DIEGO, Jan. 10, 2020 (GLOBE NEWSWIRE) — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced a financing and co-development collaboration […]

by Nick Paul Taylor Nov 15, 2019 8:15am Sarepta Therapeutics is set to pay $48 million upfront to work with StrideBio on gene therapies. The deal gives Sarepta exclusive licenses to four CNS targets, plus an option to pay a further $42.5 million to add another four targets to the deal. In return for the initial outlay, Sarepta […]

— Multi-product collaboration will address pathogens for which the World Health Organization (WHO) has declared there is a “critical need” for new drugs due to carbapenem-resistance in Acinetobacter, Pseudomonas aeruginosa, and Enterobacteriaceae (CRE) — Qpex grants license to its current product portfolio in greater China territories to Brii Biosciences while Qpex retains all other rights […]

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), today announced the initiation of its Phase 2a study with GB-102 in patients with macular […]

– Detailed data from this trial will be presented at a medical meeting later this year – RESEARCH TRIANGLE PARK, N.C., June 18, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from a randomized Phase 2 trial which demonstrated that women with metastatic […]

AUSTIN, Texas–(BUSINESS WIRE)– Elligo Health Research, an integrated research organization (IRO), announced today $20 million in Series C funding led by Piper Jaffray Merchant Banking, a division of Piper Jaffray, with participation from all lead Series A and B investors. This funding is the second investment the company has gained in a little over a year […]

Multi-target deal will utilize StrideBio’s platform to identify unique AAV capsids for delivery of gene therapies targeting neurological diseases, including Friedreich’s Ataxia DURHAM, N.C., March 28, 2019 /PRNewswire/ — StrideBio, Inc, a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the signing of a collaboration and license agreement with Takeda Pharmaceutical Company […]

Azarbarzin brings vast experience in medical devices, surgical stapling, innovation, and successful execution of growth strategies   Blue Ash, OH – January 30, 2019 – Standard Bariatrics, Inc. today announced the appointment of Kurt Azarbarzin as Chairman of the Board of Directors, effective immediately. Azarbarzin, currently serving as Chief Technology Officer at CONMED Corporation (“CONMED”), brings […]

Qpex to continue partnership with BARDA with total award up to $132 million SAN DIEGO, Oct. 22, 2018 /PRNewswire/ — Qpex Biopharma today announced the closing of a $33 million Series A financing and launch of the infectious disease company. Qpex is focused on developing new antibiotics to combat the growing threat of global antimicrobial resistance. […]

April 18, 2018 — CINCINNATI, OH — Standard Bariatrics, Inc., an innovator of bariatric surgical devices, has raised a Series A round of financing. RiverVest Venture Partners led the round with participation from Hatteras Venture Partners, Queen City Angels/QCA First Fund V, Emergent Medical Partners, Accelerant Fund and North Coast Angels. The size of the round is undisclosed.

March 07, 2018 — RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced the pricing of an underwritten public offering of 3,400,000 shares of its common stock at a public offering price of $29.50, for total gross proceeds of $100.3 million.

Oct. 31, 2017 (MARKETWIRED) — DURHAM, NC — Ribometrix, Inc., a biotech company dedicated to discovering and developing small molecule modulators of RNA to treat disease, has raised $7.5 million in seed capital.

May 30, 2017 (GLOBE NEWSWIRE) — RESEARCH TRIANGLE PARK, N.C. — G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a study of its lead CDK4/6 inhibitor trilaciclib as a first-line combination treatment in patients with extensive stage small-cell lung cancer (SCLC) will be presented in a poster session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 2 – 6 at McCormick Place in Chicago.

RESEARCH TRIANGLE PARK, N.C., January 6, 2017, – Viamet Pharmaceuticals, Inc. today reported positive efficacy and safety results from REVIVE (Recurrent Vulvovaginal Candidiasis Inhibition: an Oral VT-1161 Tablet Evaluation), a Phase 2b clinical trial of VT-1161 for the treatment of recurrent vulvovaginal candidiasis, or RVVC. RVVC is defined as three or more episodes of acute vulvovaginal candidiasis, or AVVC (commonly referred to as a vaginal yeast infection), in a 12-month period. VT-1161, the company’s lead product candidate, is a highly potent and selective, orally available inhibitor of fungal CYP51.

CARY, N.C.– Medfusion, a leading provider of patient experience solutions, today announced that GE Healthcare has named the company as the inaugural member of its Centricity™ Partner Program. GE Healthcare’s Centricity™ Partner Program recognizes Centricity software and services partners and enables them to collaboratively test software and services with GE Healthcare solutions.

Redwood City, CA – June 21, 2016 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced that two prominent industry executives have joined its management team. 

Wyoming is improving its birth outcomes one downloader at a time. An interactive mobile app—Due Date Plus—that the state Medicaid office developed for pregnant women is redefining prenatal education and transforming how Medicaid meets the needs of its pregnant population.

At our entrepreneurial support organization, the Council for Entrepreneurial Development (CED), we often joke about adhering to the proper dress and catering code for our networking events: jeans and beer for tech; suits, wine and cocktails for life sciences.

When I was a senior in college, my career goals were fairly simple. I wanted to work for a company that was doing something I cared deeply about. So, when I started actually looking for jobs, I limited my search to non-profits, because, well, in my mind: non-profits = world changers, for-profits = EVIL EMPIRES OF EVIL.

IRVINE, California & BALTIMORE, Maryland – (BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, and GrayBug, Inc., a venture-stage pharmaceutical company developing microparticle controlled release drug delivery technologies for the treatment of ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced a research collaboration and license agreement to deliver certain of Aerie’s preclinical product candidates to both the front and back of the eye using GrayBug’s proprietary technology.

Research Triangle Park, NC, May 7, 2015 – Spyryx Biosciences, Inc., a privately-held biopharmaceutical company developing novel therapeutics for respiratory diseases, including cystic fibrosis (CF) and chronic obstructive pulmonary disorder (COPD), announced today that it has secured $18 million in Series A venture capital financing from Canaan Partners, Hatteras Venture Partners and 5AM Ventures.

BALTIMORE (March 17, 2015) – GrayBug Inc., a privately held pharmaceutical company developing drug delivery therapies and sustained-release compounds for the treatment of eye diseases, today announced that its co-founder and Chief Scientific Officer Dr. Justin Hanes will deliver the keynote presentation, titled “The Dawn of Nanotechnology in Ocular Therapeutics” at the 7th Ocular Diseases Drug Discovery Conference at the Westin San Diego on Thursday, March 19 at 8:00 a.m.

CAMBRIDGE, Mass. — Feb. 3, 2015 — Lysosomal Therapeutics Inc. (LTI), a company leveraging its expertise in lysosomal biology to develop novel small molecules for use in the treatment of neurodegenerative diseases, announced today it has raised $20 million in Series A financing.

ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside order tramadol online mastercard Biomedical, Inc., today announced the closing of a $16 million Series B financing. The financing included new investor RusnanoMedInvest (RMI) and existing investors Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund.

RESEARCH PARK TRIANGLE, NC, June 17, 2014 – G1 Therapeutics, Inc., a privately held pharmaceutical company that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications, today announced that Raj Malik, MD, has joined the company as Chief Medical Officer and Greg Mossinghoff has been named Chief Business Officer.

MORRISVILLE, N.C. (Business Wire) March 11, 2014 – Clinipace Worldwide, a global digital contract research organization (dCRO), announced today the closing of its merger with Choice Pharma, a Pan-Asian contract research organization. Bringing these organizations together strengthens Clinipace Worldwide’s operational and therapeutic expertise in Asia, a region in high demand by Clinipace’s clients.

Chapel Hill, NC, October 16, 2013 – G1 Therapeutics, Inc. today announced that it has raised a Series A financing of $12.5M that will enable the advancement of its lead clinical candidate through the filing of an Investigational New Drug application (IND) and initial clinical testing. The financing was led by MedImmune Ventures. Co-investors include Hatteras Venture Partners and Mountain Group Capital. 

ATLANTA, GA – Clearside Biomedical, Inc., a privately held company specializing in the research and development of ophthalmic pharmaceuticals, today announced the successful dosing of patients in a safety and tolerability clinical study using its proprietary ocular microinjection platform to deliver therapeutics to treat retinal disease.

MALVERN, PA – (Business Wire) – PhaseBio Pharmaceuticals, Inc. announced today positive results from its Phase I/IIa single and multiple ascending dose clinical study with Glymera™, a recombinant glucagon-like peptide-1 (GLP-1) analogue for the treatment of hyperglycemia in patients with type 2 diabetes. In a dose dependent manner, Glymera™ demonstrated highly statistically significant reductions in fasting glucose glycemic load following meal tolerance testing, and average daily glucose measured through continuous glucose monitoring following 4 weeks of dosing.

Research to focus on novel agricultural chemicals with new modes of action MIDLAND, MICHIGAN and MORRISVILLE, NORTH CAROLINA – Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), and Viamet Pharmaceuticals, Inc. have entered into a crop protection research, option, and license agreement to evaluate the potential use of Metallophile™ Technology to […]

Ann Arbor, MI – HistoSonics, Inc. today announced it has secured $11 million in a Series A financing led by Venture Investors of Ann Arbor, Michigan and Madison, Wisconsin. Venture Investors worked closely with Fletcher Spaght Ventures, Hatteras Venture Partners, Early Stage Partners, and TGap Ventures to assemble an outstanding investment syndicate.

San Jose, CA – SpineAlign Medical, Inc. (formerly SpineWorks Medical, Inc.) announced today the successful treatment of the first patient in its FDA Investigational Device Exemption (IDE) feasibility study. The SpineAlign System is designed for the treatment of vertebral compression fractures and features an innovative nitinol implant designed to achieve vertebral body reconstruction via a transpedicular, minimally-invasive approach.

Morrisville, NC – Phase Bioscience, Inc., a development stage biopharmaceutical company, announced today that Dr. Craig Rosen has joined the company as Executive Chairman of the Board, effective immediately.

Durham, NC – Phase Bioscience, Inc., a development stage biotechnology company, announced today that it has successfully raised an additional $5.4 million in Series B financing, bringing the total Series B round to $6.6 million.